admin

Medical Marijuana Inc (OTCMKTS:MJNA) continues to trade a bit soft. There are really two key points of comparison here that make this important. First, the stock has been relatively weak in light of how many press releases and catalysts seem to constantly be pressed into the market from the company. Second, we see plenty of […]

by

NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being […]

by

Wrapmail Inc (OTCMKTS:WRAP) is a micro-cap stock that’s clearly begun to spur some interest among players in the marketplace as shares bounce up off recent lows. WRAP stock has been powering higher of late, pushed in part by its recent announcement that they have acquired 100% of HealthMax Group (HealthMaxgroup.com), “thereby entering the multi-billion dollar cannabis […]

by

Glioblastoma is an aggressive form of cancer that attacks the brain. It is, for now, an extremely difficult disease to overcome — most people live about 15 months after radiation therapy and chemotherapy — but that is very likely about to change, thanks to marijuana. A new treatment incorporating weed’s active compounds has just been […]

by

NEW YORK – (Uptick Newswire – March 8, 2017) – Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome […]

by

In what is being heralded as a breakthrough for cancer research, GW Pharmaceuticals announced on Tuesday positive results from a study using a combination of cannabidiol and tetrahydrocannabinol to treat an aggressive form of brain cancer. Glioblastoma multiforme, or GBM is a “particularly aggressive brain tumor, with a poor prognosis,” according to the British-based biopharmaceutical company focused on […]

by

Vitality Biopharma Inc (OTCMKTS:VBIO) has been under heavy distribution basically since it started trading in 2012 under a different ticker. Despite being ostensibly in the cannabis patch, the stock was unable to mount much upside during the 2016 Green Rush. However, perhaps even worse, we have seen a massive rise in volume without much in […]

by

NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being […]

by

NEW YORK, March 07, 2017 — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced enrollment of 40 patients and commencement of its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum. The study is being conducted by […]

NEW YORK – (Uptick Newswire – March 8, 2017) – Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome […]

Medical Marijuana Inc (OTCMKTS:MJNA) recently saw a drop back to $0.10 support levels after the stock failed to take out $0.268 previous highs of November. MJNA remains an Investors favorite and a staple among the top most traded stocks on the entire exchange especially when pot stocks heat up. MJNA is one of the original pot […]

LONDON, March 07, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Scott Giacobello as Chief Financial Officer on 6 March 2017. Reporting to GW’s Chief Executive Officer […]

Final data collection for primary outcome measure is estimated to complete in April 2017, with the full study estimated to complete in June 2017. “Successfully enrolling patients in this IBS clinical trial, which marks the first advancement in cannabinoid research for treatment of IBS in medical history, is an exciting new milestone for AXIM’s clinical […]

LONDON, March 02, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, 8 […]